Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Breast Neoplasms 1

Interventions

Carboplatin 88 pembrolizumab 85 Paclitaxel 71 Cyclophosphamide 63 Capecitabine 38 Doxorubicin 37 Taxes 29 130-nm albumin-bound paclitaxel 29 Cisplatin 25 Albumin-Bound Paclitaxel 22 Epirubicin 21 Drug Therapy 21 Docetaxel 20 sacituzumab govitecan 19 olaparib 19 camrelizumab 18 atezolizumab 18 Gemcitabine 17 eribulin 16 durvalumab 16 Bevacizumab 16 Radiotherapy 15 toripalimab 14 Specimen Handling 14 Biopsy 13 Everolimus 12 Magnetic Resonance Spectroscopy 11 apatinib 10 Nivolumab 10 talazoparib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Triple Negative Breast Neoplasms × parsaclisib × Clear all

NCT04142554 2020-11-03

LCCC1820

UNC Lineberger Comprehensive Cancer Center

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡